STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

The investigators hypothesize that patients with mCRC RAS-mutant eligible for a second line treatment with good prognostic features, identified as single metastatic site, long progression free survival (PFS) in first line treatment, might benefit from a personalized approach, with less intensive treatment with regorafenib as part of a continuum-of-care strategy aimed at ensuring quality of life and extending survival.

Trial Details

NCT ID

NCT07213570

Phase

PHASE2

Sponsor

National Cancer Institute, Naples

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

standard second line treatment, at discretion of the investigator
Regorafenib (BAY73-4506)

Locations (sample)

Naples, Italy, Italy|40.85216,14.26811

Key Eligibility Criteria

Written informed consent to study procedures and to correlative studies.
Either sex aged ≥ 18.
Histologically proven of colorectal adenocarcinoma.
Diagnosis of metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →